The Latest Breaking News from Edwards Lifesciences

Edwards Lifesciences Corp (NYSE:EW) posted a Q1 adjusted EPS of $0.60, compared to $0.54 posted a year ago and beating the consensus of $0.57. Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion. Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's…

Growing demand from an aging population to track their diseases and increased focus on critical surgical procedures with lesser COVID-19 pressures on hospitals make the medical devices industry’s prospects bright. Moreover, the integration of emerging technologies and continued innovations should drive the industry’s growth. Therefore, prominent players in this space,…

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

If history is any guide, there may be trouble ahead for shares of Edwards Lifesciences (NYSE:EW). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

Heart device company Edwards Lifesciences Corp (NYSE: EW) posted 

Edwards Lifesciences (NYSE:EW) reported its Q4 earnings results on Wednesday, January 26, 2022 at 04:15 PM. Here's what investors need to know about the announcement.

Edwards Lifesciences (NYSE:EW) is set to give its latest quarterly earnings report on Wednesday, 2022-01-26. Here's what investors need to know before the announcement. Analysts estimate that Edwards Lifesciences will likely report an Earnings Per Share (EPS) of $0.55.